FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma.
- Luxembourg Center of Neuropathology
Fibroblast growth factor receptor inhibitors are currently in clinical development. A subset of glioblastomas carries gene fusion of FGFR3 and transforming acidic coiled-coil protein 3. The prevalence of other FGFR3 alterations in glioma is currently unclear.We performed RT-PCR in 101 glioblastoma samples to detect FGFR3–TACC3 fusions (“RT-PCR cohort”) and correlated results with FGFR3 immunohistochemistry (IHC). Further, we applied FGFR3 IHC in 552 tissue microarray glioma samples (“TMA cohort”) and validated these results in two external cohorts with 319 patients. Gene panel sequencing was carried out in 88 samples (“NGS cohort”) to identify other possible FGFR3 alterations. Molecular modelling was performed on newly detected mutations.In the “RT-PCR cohort”, we identified FGFR3-TACC3 fusions in 2/101 glioblastomas. Positive IHC staining was observed in 73/1024 tumor samples of which 10 were strongly positive. In the “NGS cohort” we identified FGFR3-fusions in 9/88 cases, FGFR3 amplification in 2/88 cases and FGFR3 gene mutations in 7/88 cases in targeted sequencing. All FGFR3 fusions and amplifications and a novel FGFR3 K649R missense mutation were associated with FGFR3 overexpression (sensitivity and specificity of 93 and 95% respectively, at cutoff IHC score >7). Modelling of these data indicated that Tyr647, a residue phosphorylated as a part of FGFR3 activation is affected by the K649R mutation. FGFR3 immunohistochemistry is a useful screening tool for the detection of FGFR3 alterations and could be included in the workflow for IDH wildtype glioma diagnostics. Samples with positive FGFR3 staining could then be selected for NGS-based diagnostic tools.